Anthill Agency’s Post

💡 Spotlight on Today's LISA Hero: Alexander Herzog 💡 Alexander is Secretary General at PHARMIG, the Association of the Austrian Pharmaceutical Industry. He is also Member of the Council at IFPMA - International Federation of Pharmaceutical Manufacturers & Associations and Member of the Advisory Board of LISA - Life Science Austria. 🎤 Alexander, what is your role in the Life Science ecosystem? 🔊 In PHARMIG, we represent the entire pharmaceutical industry in Austria, from small companies to large corporations, whether research or sales subsidiaries. We do everything in our power to strengthen Austria as a pharmaceutical location and to keep it internationally competitive. Because one thing is clear to us and we always focus on it: our industry, and therefore also the life science sector, are industries of the future. Strengthening them brings multiple benefits. 🎤 How do you perceive Austria as a location for life sciences? 🔊 We have a very good infrastructure in Austria, enormously committed and competent researchers and can therefore also compete internationally in the life science sector. There are many hidden champions in Austria that play a part in the global market or are even global market leaders. The life science sector is really leading the way here! 🎤 What are the trends you observe in the Life Science sector in Austria? 🔊 According to the latest media reports, the total volume of #investment has fallen from 1 billion Euro to 700 million Euro in 2023. At the same time we see a certain awareness at a political level that we have a vibrant and internationally competitive life science sector in Austria. It is therefore all the more important not to threaten this by investing less, but quite the opposite: to keep at it in order to remain internationally competitive. Photo Credit: © Stefan Csaky

14-15 March – Barcelona, Spain   Our final session at Clinigen Insights sees Claudia Martínez, Head of Research at the Access to Medicines Foundation, discuss the evolving landscape of access strategy integration within pharmaceutical companies' new product development. Gain invaluable insights into our industry's concerted efforts to enhance access in Low- and Middle-Income Countries (LMIC).   The session will be followed by a panel discussion and Q&A featuring experts from our Clinigen Regulatory, Commercial, and Consulting teams to delve into the nuances of the transition from Managed Access program to commercial strategy and explore novel approaches to non-launch market access for emerging treatments.   Find out more and RSVP (while places are still available): https://bit.ly/3GF1SJm   #managedaccess #expandedaccess #earlyaccess #realworlddata

On July 15th, Pharma Innovation Forum Greece (PIF), initiated a public discussion about a “Framework Agreement” for a collaborative national pharmaceutical strategy in Greece. Labrina Barmpetaki, President of PIF and Ioannis Kotsiopoulos, PMP, MSc, PhD, General Manager of PIF, addressed the need to ensure timely and equitable access to innovative treatments, improve pharmaceutical policy sustainability and enhance Greece's competitiveness in South-East Europe. The agreement involves a trilateral decision-making structure including the Government, Pharmaceutical Industry Associations, and Patient Associations, with commitments to adequate funding, digital tools for demand control and increased investment in clinical research. PIF calls on the Greek Government and all stakeholders to collaborate in implementing this agreement as the foundation for a sustainable pharmaceutical policy for the benefit of patients and the national economy. #pifgreece #FrameWorkAgreeement

💊 Arterium took part in the Congress "Pharmacies of the World-2024" 🌍 🔸 This is an annual large-scale event in Ukraine that brings together players in the pharmacy retail and distribution sectors, pharmaceutical industry professionals, and regulatory bodies. 🔸 At the event, industry experts introduced participants to promising trends in the development of distribution and retail, discussed investments in the pharmaceutical sector, and presented analytical reviews and economic forecasts for the development of Ukraine's pharmaceutical market. This, in turn, will help build a business development strategy. 🔸 Such a strategy needs to be based on changes and initiatives from regulators, another key topic of the congress. This topic was addressed by Sergey Sur, Director of Arterium LTD. The Doctor of Pharmaceutical Sciences compared WHO's Good Regulatory Practices with the current regulatory practices in Ukraine. To reconcile the differences between them, stakeholders in Ukraine need to address several issues. In his presentation, Serhii Sur offered his own proposals for improving Ukraine's regulatory system. 🔸 We hope this will aid in the development of the pharmaceutical business in our country. Morion Proxima Research #Arterium #PharmaceuticalBusiness #developmentstrategy #regulatorysystem #Congress

Kyriakos Berberian, our General Manager for Greece, Cyprus and Malta, spoke to @iatronet.gr about the reforms that will ensure a stable, efficient, and sustainable pharmaceutical policy in Greece: “It is vital to adopt a stable and predictable framework that will allow the adjustment of the pharmaceutical budget to meet the growing needs of patients” Click to read the full interview. https://lnkd.in/dAR-ZA9K #genesispharma

Register to the XVI Foresight Training Course “Repurposing to cover unmet needs: the current scenario in Europe and the proposed changes to the Pharmaceutical Legislation” organised by Gianni Benzi ONLUS - Pharmacological Research Foundation and Università degli Studi di Bari Aldo Moro! It will be held on 18 December 2022 in Bari, Italy and online. ℹ️ The course will focus on #repurposing, #regulatoryscience, #innovative #methodologies and #pharmaceuticallegislation, #paediatrics and #rarediseases ⬇️Registration and agenda https://lnkd.in/dFne4MpT #c4c, #conect4children, EFPIA - European Federation of Pharmaceutical Industries and Associations Innovative Health Initiative (IHI)

Eurasian Pharma Awards 2023: Olainfarm and Meros Pharm are the winners in the nomination “Partnership of the Year” In 2023 in the competition for the Eurasian Pharma Awards in the nomination “Partnership of the Year” the award was presented to Olainfarm and Meros Pharm. The transformation of collaboration between Olainfarm, a leading pharmaceutical company in the Baltics, and Meros Pharm, a leader in pharmaceutical distribution in Uzbekistan, along with increased investments in product promotion and improvements in both international and local logistics, has yielded tangible results that allow to develop ambitious plans for the future. The exclusive agreement has ensured the availability of Olainfarm products in over 4,000 pharmacies and has led to a 65% increase in sales compared to the previous year. Elena Bushberg, Executive Director of Olainfarm, highlighted: «As a proverb says a tree is held by its roots, and a person is held by their family and heritage. I would add that success in business is held by good partners». Learn more >> https://lnkd.in/em2a6fNM  #EurasianPharmaAwards #GlobalPharmaLeadersClub #Pharma #conferences #Uzbekistan #Tashkent #Samarkand #EurasianPharmaceuticalSummit #awards

Reflecting on valuable information sharing between national trade associations This morning, I had the privilege of joining an insightful conversation and information sharing between industry experts from The Association of the British Pharmaceutical Industry (ABPI) and Danish Association of the Pharmaceutical Industry - Lif - Lægemiddelindustriforeningen The conversation focused on regulatory value and access policy environment for medicines in the UK and Denmark, sharing notes on current complexities, challenges and opportunities within the regulatory frameworks and the UK's appeal as a destination for life sciences investment. Key takeaways include the potential for regulatory improvements, the impact of international collaborations, and innovative pathways to market access for new medicines in both territories, underscoring the necessity of a patient-centric approach in developing regulatory systems for innovation in the pharmaceutical landscape Thanks to Daniel O'Connor, Orban Holdgate, Andy Collier, Louise Broe, Pernille Langgaard-Lauridsen, Thomas Klit Christensen and Joakim Steen Barron-Mikkelsen for a constructive and enlightening session. More of this please! #PharmaceuticalIndustry #RegulatoryAffairs #HealthTechnologyAssessment #InnovationInHealthcare #RegulatoryInnovation

Eurasian Pharma Awards 2023: Olainfarm and Meros Pharm are the winners in the nomination “Partnership of the Year” In 2023 in the competition for the Eurasian Pharma Awards in the nomination “Partnership of the Year” the award was presented to Olainfarm and Meros Pharm. The transformation of collaboration between Olainfarm, a leading pharmaceutical company in the Baltics, and Meros Pharm, a leader in pharmaceutical distribution in Uzbekistan, along with increased investments in product promotion and improvements in both international and local logistics, has yielded tangible results that allow to develop ambitious plans for the future. The exclusive agreement has ensured the availability of Olainfarm products in over 4,000 pharmacies and has led to a 65% increase in sales compared to the previous year. Elena Bushberg, Executive Director of Olainfarm, highlighted: «As a proverb says a tree is held by its roots, and a person is held by their family and heritage. I would add that success in business is held by good partners». Learn more >> https://lnkd.in/em2a6fNM  #EurasianPharmaAwards #GlobalPharmaLeadersClub #Pharma #conferences #Uzbekistan #Tashkent #Samarkand #EurasianPharmaceuticalSummit #awards

Elomatic returns to Sweden to offer services for controlled environments in the pharmaceutical industry! 💉🏭 The company is continuing its growth in the Nordics and expanding to Sweden together with partners, Wicket AB and NAYA LIFE SCIENCES. The service offering is focused on controlled environments, such as modern cleanrooms, especially within the pharmaceutical industry. As the pharmaceutical market in Sweden has grown, several regions have turned into hubs for prominent life science and pharmaceutical start-ups. Sweden has also made substantial investments in research and development and is known for its high-quality pharmaceutical production. “We are excited to be returning to the Swedish market. We see that our services will contribute to further strengthen pharmaceutical companies’ competitiveness and support their success with future-proof solutions with modern design.” says Mona Åkerholm, Senior Vice President, Pharma, Elomatic. Read more about the news from here➡️https://lnkd.in/d3A2GF4D #Elomatic #BuildingTomorrow #ControlledEnvironments #Cleanrooms #Pharmaceuticalindustry